Eli Lilly and Company, a pharmaceutical company based in Indianapolis, Indiana, revealed it has teamed up with Amazon Pharmacy to help deliver its Zepbound weight loss drug and other medicines straight to customers' homes.
It struck a partnership deal with the online pharmacy subsidiary of Amazon Inc. just four months after obtaining the required regulatory approval to sell its diabetes treatment under a different name and category: weight loss.
Lilly's Weight Loss Treatment
According to CBS News, Eli Lilly's Tirzepatide drug, currently sold as a Mounjaro brand for diabetes, is now on the market under the new name Zepbound. It is also advertised as a weight-loss medication administered using an injection pen.
The company reportedly started selling Zepbound earlier this year. The drugs are directly sold to patients. Patients consult with doctors and obtain prescriptions from digital pharmacies, and the drugs are delivered to them.
Amazon Pharmacy Added as Home Delivery Option
Its partnership with Amazon's pharmacy unit allows patients and customers to obtain their medications quickly. In addition to Amazon Pharmacy, Eli Lilly delivers drugs to its customers via Truepill.
"Lilly has selected Amazon Pharmacy as a dispensing pharmacy option, allowing patients to receive fast, free delivery of medications and 24/7 access to clinical pharmacists," Dr. Vin Gupta, Amazon Pharmacy's chief medical officer, said in a press release. "To help patients being treated for diabetes, obesity, and migraine, Amazon Pharmacy is now offering home delivery of select medications through LillyDirect."
Dr. Gupta added, "Lilly has selected Amazon Pharmacy to serve as a third-party dispensing provider for LillyDirect Pharmacy Solutions, delivering prescribed Lilly medications directly to a patient's home."
Photo by: James Yarema/Unsplash


The Maire - EuroChem Case: Three Lessons for Global Business
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI
Google Halts UK YouTube TV Measurement Service After Legal Action
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand
ASML’s EUV Monopoly Powers the Global AI Chip Boom
Anthropic Raises 2026 Revenue Outlook by 20% but Delays Path to Profitability
C3.ai in Merger Talks With Automation Anywhere as AI Software Industry Sees Consolidation
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal
Elon Musk Reportedly Eyes June 2026 SpaceX IPO Timed With Planetary Alignment and Birthday
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 



